Vhl is required for normal pancreatic Β cell function and the maintenance of Β cell mass with age in mice

Laboratory Investigation

Volumn 91, Issue 4, 2011, Pages 527-538

  Choi, Diana ^a,b   Cai, Erica P ^a,b   Schroer, Stephanie A ^b   Wang, Linyuan ^a,b   Woo, Minna ^a,b,c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NONE   (Canada)

Author keywords

angiogenesis; diabetes mellitus; GLUT2; hypoxia inducible factor; insulin secretion; von Hippel Lindau; cell

Indexed keywords

CRE RECOMBINASE; ERYTHROPOIETIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INSULIN; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL STRUCTURE; CONTROLLED STUDY; GENE DELETION; GENE LOSS; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; KNOCKOUT MOUSE; LOXP SITE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 79953167224     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.207     Document Type: Article

References (61)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2009;87:4-14.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053. (Pubitemid 38579764)
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19. (Pubitemid 36237741)
4. Rhodes CJ. Type 2 diabetes-a matter of b-cell life and death? Science 2005;307:380-384. (Pubitemid 40139973)
5. Jetton TL, Lausier J, LaRock K, et al. Mechanisms of compensatory betacell growth in insulin resistant rats: roles of Akt kinase. Diabetes 2005;54:2294-2304. (Pubitemid 41134255)
6. Liu YQ, Jetton TL, Leahy JL. Beta-cell adaptation to insulin resistance: increased pyruvate carboxylase activity and anaplerosis in islets of Zucker fatty rats. J Biol Chem 2002;277:39163-39168. (Pubitemid 35190884)
7. Steil GM, Trivedi N, Jonas JC, et al. Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol Endocrinol Metab 2001;280:E788-E796.
8. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased apoptosis in humans with type-2 diabetes. Diabetes 2003;52: 102-110. (Pubitemid 36042113)
9. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Med 1998;15:297-303. (Pubitemid 28168509)
10. Poitout V, Roberston RP. Secondary beta-cell failure in type 2 diabetes. A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002;143:339-342. (Pubitemid 34107184)
11. Prentki M, Nolan CJ. Islet b-cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812. (Pubitemid 44033300)
12. Gunton JE, Kulkarni RN, Yim S, et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 2005;122:337-349. (Pubitemid 41127137)
13. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996;76:839-885. (Pubitemid 26286080)
14. O'Rourke JF, Dachs GU, Gleadle JM, et al. Hypoxia response elements. Oncol Res 1997;9:327-332. (Pubitemid 127825986)
15. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;14:1983-1991. (Pubitemid 30637348)
16. Wenger RH, Gassman M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997;378:609-616. (Pubitemid 27361853)
17. Bonventre JB. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002;11:43-48.
18. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 2006;7:437-448. (Pubitemid 44012284)
19. Yellon DM, Hausenloy DJ. Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005;2:568-575. (Pubitemid 41655660)
20. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cellspecific gene knock-outs using cre recombinase. J Biol Chem 1999;274:305-315. (Pubitemid 29035064)
21. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 2005;94:9102-9107.
22. Liadis N, Murakami K, Eweida M, et al. Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol Cell Biol 2005;25:3620-3629. (Pubitemid 40559568)
23. Wijesekara N, Konrad D, Eweida M, et al. Muscle-specific PTEN deletion protects against insulin resistance and diabetes. Mol Cell Biol 2005;25:1135-1145. (Pubitemid 40165819)
24. Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic autoimmune encephalomyelitis. J Neuroimmunol 2006;172:27-37. (Pubitemid 43279681)
25. Choudhury AI, Heffron H, Smith MA, et al. The role of the insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 2005;115:940-950. (Pubitemid 40489398)
26. Nguyen KT, Tajmir P, Lin CH, et al. Essential role of Pten in body size determination and pancreatic b-cell homeostasis in vivo. Mol Cell Biol 2006;26:4511-4518. (Pubitemid 43877571)
27. Cantley J, Selman C, Shukla D, et al. Deletion of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 2009;119:125-135.
28. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-2080. (Pubitemid 39297859)
29. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007;405:1-9. (Pubitemid 46999919)
30. Beatens D, Malaisse-Lagae F, Perrelet A, et al. Endocrine pancreas: three-dimensional reconstruction shows two types of islets of Langerhans. Science 1979;206:1323-1325. (Pubitemid 10170025)
31. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2- regulated gene expression. FASEB J 2002;16:1151-1162. (Pubitemid 34815403)
32. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684. (Pubitemid 36749216)
33. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1998;81:620-623.
34. Zanjani ED, Ascensao JL, McGlave PB, et al. Studies on the liver to kidney switch of erythropoietin production. J Clin Invest 1981;67: 1183-1188. (Pubitemid 11090560)
35. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-95. (Pubitemid 40066704)
36. Spivak JL, Pham T, Isaacs M, et al. Erythropoietin is both a mitogen and a survival factor. Blood 1991;77:1228-1233.
37. Fenjves ES, Ochoa MS, Cabrera O, et al. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003;75:1356-1360. (Pubitemid 36513048)
38. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275. (Pubitemid 29246458)
39. Lonser RR, Glen GM, Walther M, et al. Von Hippel-Lindau disease. Lancet 2003;361:2059-2067. (Pubitemid 36695052)
40. Shen HC, Adem A, Ylaya K, et al. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One 2009;4:e4897.
41. Puri S, Cano DA, Hebrok M. A role for von Hippel-Lindau protein in pancreatic beta-cell function. Diabetes 2009;58:433-441.
42. Zehetner J, Danzer C, Collins S, et al. PVHL is a regulator of glucose metabolism and insulin secretion in pancreatic beta cells. Genes Dev 2008;22:3135-3146.
43. Bossenmeyer-Pourle C, Koziel V, Daval JL. CPP32/Caspase-3-like proteases in hypoxia-induced apoptosis in developing brain neurons. Mol Brain Res 1999;71:225-237. (Pubitemid 29492967)
44. Todor A, Sharov VG, Tanhehco EJ, et al. Hypoxia-induced cleavage of caspase-3 and DFF45/ICAD in human failed cardiomyocytes. Am J Physiol Heart Circ Physiol 2002;283:H990-H995.
45. Heinis M, Simon MT, Duvillié B. New insights into endocrine pancreatic development: the role of environmental factors. Horm Res Paediatr 2010;74:77-82.
46. Heinis M, Simon MT, Ilc K, et al. Oxygen tension regulates pancreatic b-cell differentiation through HIF1. Diabetes 2010;59: 662-669.
47. Gradwohl G, Dierich A, LeMeur M, et al. Neurogenin-3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 2000;97:1607-1611. (Pubitemid 30118489)
48. Bonny C, Roduit R, Gremlich S, et al. The loss of GLUT2 expression in the pancreatic beta-cells of diabetic db/db mice is associated with an impaired DNA-binding activity of islet-specific transacting factors. Mol Cell Endocrinol 1997;135:59-65. (Pubitemid 28010414)
49. Ohneda M, Johnson JH, Inman LR, et al. GLUT2 expression and function in beta-cells of GK rats with NIDDM: dissociation between reductions in glucose transport and glucose-stimulated insulin secretion. Diabetes 1993;42:1065-1072. (Pubitemid 23182173)
50. Li X, Zhang L, Meshinchi S, et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006;55:2965-2973. (Pubitemid 44929429)
51. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993;42:12-21. (Pubitemid 23013790)
52. Narimiya M, Yamada H, Matsuba I, et al. The effect of hypoxia on insulin and glucagon secretion in the perfused pancreas of the rat. Endocrinology 1982;111:1010-1014.
53. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806. (Pubitemid 34000783)
54. Fenjves ES, Ochoa MS, Gay-Ravinstein C, et al. Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation 2004;77:13-18. (Pubitemid 38116865)
55. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1a-degradative pathway. J Biol chem 2002;277:29936-29944.
56. Liu YV, Baek JH, Zhang H, et al. RACK1 Competes with HSP90 for binding to HIF-1a and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1a. Mol Cell 2007;25:207-217. (Pubitemid 46109612)
57. Flü gel D, Gö rlach A, Michiels C, et alGlycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1 and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 2007, 27: 3253-3265. (Pubitemid 46685205)
58. Kong X, Lin Z, Liang D, et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxiainducible factor 1a. Mol Cell Biol 2006;26:2019-2028. (Pubitemid 43346906)
59. Ohori K, Miura T, Tanno M, et al. Ser9-phosphorylation of mitochondrial GSK-3{beta} is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 2008;295:2079-2086.
60. Xu B, Dong GH, Liu H, et al. human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci 2005;35:161-168. (Pubitemid 40677109)
61. Guillam MT, Hümmler E, Schaerer E, et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 1997;17:327-330. (Pubitemid 27475998)